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Abstract The prevalence of both Alzheimer’s disease (AD)
and vascular dementia (VaD) is increasing with the aging of
the population. Studies from the last several years have
shown that people with diabetes have an increased risk for
dementia and cognitive impairment. Therefore, the authors
of this consensus review tried to elaborate on the role of
diabetes, especially diabetes type 2 (T2DM) in both AD and
VaD. Based on the clinical and experimental work of sci-
entists from 18 countries participating in the International
Congress on Vascular Disorders and on literature search
using PUBMED, it can be concluded that T2DM is a risk
factor for both, AD and VaD, based on a pathology of glu-
cose utilization. This pathology is the consequence of a
disturbance of insulin-related mechanisms leading to brain
insulin resistance. Although the underlying pathological
mechanisms for AD and VaD are different in many aspects,
the contribution of T2DM and insulin resistant brain state
(IRBS) to cerebrovascular disturbances in both disorders
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cannot be neglected. Therefore, early diagnosis of metabolic
parameters including those relevant for T2DM is required.
Moreover, it is possible that therapeutic options utilized
today for diabetes treatment may also have an effect on the
risk for dementia. T2DM/IRBS contribute to pathological
processes in AD and VaD.
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GLUT3 Glucose transporter 3
GM Grey matter
GSK3b Glycogen synthase kinase 3 b
HOMA-IR Homeostatic model assessment of insulin
resistance
HNE 4-Hydroxynonenal
IDE Insulin degrading enzyme
ICV Intracerebroventricular
IGF-1R Insulin-like growth factor 1 receptor
IR Insulin receptor
IRBS Insulin resistant brain state
IRb Insulin receptor subunit b
IRS1 Insulin receptor substrate-1
IRS-1pS616 Serin-phosphorylated insulin receptor
substrate-1
Hakan Yaman
hakanyam@yahoo.com
Zheng G. Zhang
ZZHANG1@hfhs.org; zhazh@neuro.hfh.edu
Tali Cukierman-Yaffe
tcukierm@gmail.com
1 Center of Mental Health, Department Psychiatry,
Psychosomatics and Psychotherapy, University Hospital
Wu¨rzburg, 97080 Wu¨rzburg, Germany
2 Center for Aging and Associated Diseases, Helmy Institute of
Medical Science, Zewail City of Science and Technology,
Giza, Egypt
3 Department of Neurology, Neurosurgery and Psychiatry,
University of Medicine and Pharmacy Carol Davila
Bucharest, S Plaiul Independentei 169, Sector 5,
050098 Bucharest, Romania
4 Department of Neurology, Hallym Hospital, 900-4
Jakjeon-dong, Gyeyang-gu, Incheon-si 407-060, Korea
5 Department of Neurology, Henry Ford Hospital, Detroit,
MI, USA
6 The Center for Successful Aging with Diabetes,
Endocrinology Institute, Gertner Institute, Sheba Medical
Center, Epidemiology D., Sackler School of Medicine, Tel
Aviv University, Tel Aviv, Israel
7 Clinical Hospital Merkur-University, Clinic Vuk Vrhovac,
Zajcˇeva (Zajceva) 19, 10000 Zagreb, Croatia
8 Department of Child and Adolescent Psychiatry and
Psychotherapy, Psychiatric Hospital, University Zurich,
Zurich, Switzerland
9 Neuroscience Center Zurich, University of Zurich and the
ETH Zurich, Zurich, Switzerland
10 Zurich Center for Integrative Human Physiology, University
of Zurich, 5th Floor Room K118, Wagistrasse 12,
8952 Zurich, Switzerland
11 Institute of Clinical Neurobiology, Alberichgasse 5/13,
1150 Vienna, Austria
12 Biomediotronics, Enzymoic, 7 Peterlee Pl, Hebersham,
NSW 2770, Australia
13 King Fahd Medical Research Center, King Abdulaziz
University, P. O. Box 80216, Jeddah 21589, Saudi Arabia
14 Enzymoics, 7 Peterlee Place, Hebersham, NSW 2770,
Australia
15 Novel Global Community Educational Foundation, Sydney,
Australia
16 Department of Neurology, Tel Aviv University,
69978 Ramat Aviv, Israel
P. Riederer et al.
123
IRS2 Insulin receptor substrate-2
ISF Interstitial fluid
KAT Kynurenine aminotransferase
KYNAC Kynurenic acid
MCI Mild cognitive impairment
MRI Magnet resonance imaging
mTOR Mechanistic target of rapamycin
OS Oxidative stress
PCAD Pre-clinical AD
PET Positron emission tomography
PG Postprandial glycemia
PIK3CB Phosphatidylinositol-4,5-bisphosphate
3-kinase catalytic subunit beta isoform
PIK3CD Phosphatidylinositol-4,5-bisphosphate
3-kinase catalytic subunit delta
PI3 Phosphatidylinositol-3-kinase
PI3K Phosphoinositid-3-kinase
PIP3 Phosphatidylinositol (3,4,5)-triphosphate
PPARc Peroxisome proliferator-activated receptor
gamma
P-Tau Phospho-Tau-Protein
PYY Peptide YY
P53 Phosphoprotein p53
QA Quinolinic acid
RAGE Receptor for AGEs
RNA Ribonucleic acid
ROS Reactive oxygen species
sAD Sporadic Alzheimer’s disease
SGLT2 Sodium/glucose cotransporter 2
STZ Streptozotocin
T2DM Type 2 diabetes mellitus
T1DM Type 1 diabetes mellitus
VaD Vascular dementia
WM White matter
Introduction
A causative association between diabetes mellitus (DM)
and cognitive impairment has been suggested based on
clinical, epidemiological, and experimental studies (Ala-
fuzoff et al. 2009; Bitel et al. 2012; Vagelatos and Eslick
2013; Carvalho et al. 2015; Feinkohl et al. 2015; Jellinger
2015a).
In fact, recent studies demonstrate a pathophysiological
link between diabetes mellitus type II (T2DM) and cog-
nitive decline (Jellinger 2015b). This is demonstrated in
persons with DM showing that a higher risk of developing
Alzheimer’s disease (AD), vascular dementia (VaD) and
mixed-type dementia (AD plus cerebrovascular disease),
and comorbidity, in particular cerebrovascular disease,
hypertension, hypercholesterolemia, etc. increases this risk
(Jellinger 2015b; Haroon et al. 2015; Kuo et al. 2015).
Insulin resistance predicts medial temporal hyperme-
tabolism in Mild Cognitive Impairment (MCI) conversion
to AD (Willette et al. 2015b). In addition, changes in
glucose uptake in medial temporal regions in AD predict
worse memory performance (Willette et al. 2015a).
Moreover, DM facilitates cognitive decline in patients with
mild AD compared to those without comorbid DM (Jel-
linger 2015a; Ascher-Svanum et al. 2015). However, the
precise mechanisms involved in the development of AD in
diabetics are not yet fully understood, and several patho-
genic pathways have been discussed (Feinkohl et al. 2015;
Abner et al. 2016; Hao et al. 2015; Chiu et al. 2015;
Verdile et al. 2015; Bedse et al. 2015; De Felice et al.
2014), including vascular brain disease, insulin resistance,
and other metabolic effects on the brain.
In a meta-analysis, Chatterjee et al. (2016) estimated the
sex-specific relationship between women and men with
DM with incident dementia. Fourteen studies with
2310.330 individuals and 102.174 dementia cases were
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included. T2DM showed a *60% greater risk for the
development of dementia compared with those without
DM. For VaD but not for non-vascular dementia, the
additional risk is greater in women (Chatterjee et al. 2016).
In the study of Marseglia et al. (2016), the authors aimed
to identify the cognitive domains initially impaired by
diabetes and the factors that play a role in this first stage.
There were 2.305 cognitively intact participants aged
C60 years. A variety of memory tests were assessed.
Diabetes (controlled and uncontrolled) as well as predia-
betes were ascertained by clinicians. Information on vas-
cular disorders and vascular risk factors has been recorded.
Mainly uncontrolled diabetes in APOEe4 non-carriers was
related to lower performance in perceptual speed, category
fluency, and digit scan forward, and this association was
present only among participants with vascular disorders or
vascular risk factors (Marseglia et al. 2016).
One-fifth of dementia cases are caused by VaD, a dis-
order with heterogenous spectrum of cerebrovascular
pathologies (Nizam and Hyer 2007). VaD is one of the
most prevalent dementia disorders after AD (Ozbabalik
et al. 2012). The prevalence of VaD rises rapidly between
ages 65–85. People with DM as compared to those without
DM have a higher risk for developing VaD [pooled RR
2.27 [95% CI 1.94–2.66] (Gudala et al. 2013) and 2.2 (95%
CI 1.7–2.8)] (Ninomiya 2014). They are 2–4 times more
likely to develop AD and have a 1.5–2-fold greater risk for
an accelerated rate of age-related cognitive decline
(Cukierman et al. 2005). This has been demonstrated uti-
lizing both neuropsychological instruments and surrogates
such as change in MRI volumes (van den Berg et al. 2010;
van Harten et al. 2006; Reijmer et al. 2011). Individuals
with elevated blood glucose levels are at an increased risk
to develop dementia, and those with elevated blood glucose
levels have a more pronounced conversion from MCI to
AD, suggesting that disrupted glucose homeostasis could
play a more causal role in AD pathogenesis (Macauley
et al. 2015).
Observational studies have also shown an increase in the
incidence of other types of dementia than AD or VaD in
DM (Gudala et al. 2013; Macauley et al. 2015; Irie et al.
2008; Ahtiluoto et al. 2010). Therefore, the precise
mechanisms involved in the development of cognitive
impairment in diabetic patients are not yet fully understood
(Alafuzoff et al. 2009; Feinkohl et al. 2015).
Advances in the management of T2DM have enhanced
preventive and medical services and have diminished its
macro- and microvascular complications. This has led to an
increase in life expectancy of people with diabetes, how-
ever, that has increased the population at risk for cognitive
impairment and dementia (Ninomiya 2014).
Given all these aspects, the group concluded that dis-
rupted glucose homeostasis is of risk for developing
dementia. This includes diabetes-dependent cerebrovascu-
lar pathology. Therefore, the cascade of pathological
events in AD may show first onset of non-vascular
pathology followed by cerebrovascular changes, while for
VaD, cerebrovascular pathology is of primary importance.
Possible mechanisms for the relationship
between diabetes and cognitive impairment
Is cognitive impairment in patients with diabetes mellitus
type 1 (T1DM) a consequence of vascular impairment or a
separate process?
Modest cognitive impairment in patients with T1DM
does not follow any dementia pattern. Compared to healthy
controls, patients with T1DM were slower in information-
processing, but had better scores on visuospatial tests
(Brands et al. 2006). It was shown that patients with T1DM
have an increased risk of lacunar stroke (Luitse et al. 2012)
and those with additional microangiopathy had decreased
structural connectivity in posterior brain regions (van
Duinkerken et al. 2012a) and impaired function in the
ventral attention network (Van Duinkerken et al. 2012b).
However, the effect of vascular lesions on the cognitive
decline in T1DM patients is not entirely clear (Brands et al.
2006; Nunley et al. 2015; Biessels and Reijmer 2014;
Huang et al. 2014). In contrast to T2DM, T1DM begins
earlier in life and may influence brain development
(Biessels et al. 2008; de Felice and Benedict 2015) via
insulin receptors in the hypothalamus, which play a key
role in the memory system (De Felice et al. 2014; de Felice
and Benedict 2015). In a recent small study, patients with
T1DM had partly altered CSF AD biomarkers (Ouwens
et al. 2014). Levels of p-Tau were elevated similar to those
in AD patients. Another biomarker is soluble low-density
lipoprotein receptor-related protein 1 (sLRP1) protein,
which regulates efflux of beta-amyloid (Ab) from the brain
to the blood and is impaired in patients with AD (Ra-
manathan et al. 2015). T1DM patients who had elevated
levels of sLRP1 in the CSF, performed better on the cog-
nitive tests (Ouwens et al. 2014).
Hyperglycemia, which is a primary impairment in T1DM,
can cause permanent cognitive impairment, thus contrasting
the situation with hypoglycemia. In the brain of streptozo-
tocin (STZ)–T1DM rats and mice decreased neurogenesis
(Alvarez et al. 2009), mitochondrial dysfunction due to
decreased activity of respiratory chain complex I (Taurino
et al. 2012), lower release of adenosine triphosphate (ATP)
and downregulation of synaptic purinergic receptors in the
hippocampus (Duarte et al. 2007), a region involved in
learning and memory (Duarte et al. 2007), have been
reported. Moreover, STZ–T1DM animals performed poorly
on cognitive tasks (Alvarez et al. 2009).
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Taken together, it is likely that vascular risk factors
together with metabolic causes may facilitate neurode-
generation and contribute to cognitive impairment in
T1DM patients.
Atherosclerosis, stroke, and insulin resistance
Several pathogenic routes have been suggested for this
relationship. First, chronic hyperglycemia may cause cog-
nitive impairments and abnormalities in synaptic plasticity
(Jacobson et al. 2007). Tight glycemic control significantly
reduced the rate of brain atrophy over a period of
40 months in STZ-induced diabetic rats compared with the
standard glucose treatment (Biessels et al. 1996). Second,
relative insulin deficiency (also termed ‘‘insulin resis-
tance’’) may be of importance. The Hisayama study
reported an increase in the presence of neuritic plaques
with higher postprandial glycemic (PG) levels, fasting
insulin level, and insulin resistance in AD (Doi et al. 2010),
which might be also relevant for mixed forms of dementia
with VaD involvement. It is reasonable to postulate a close
association between 2-h PG levels and the risk of VaD,
because increased 2-h PG levels are associated with the
development of stroke (Thacker et al. 2011; Doi et al.
2010). Insulin resistance is associated with VaD through
atherosclerosis (De Felice et al. 2014; Fitzpatrick et al.
2009). Obesity in T2DM contributes to hyperinsulinemia
and insulin resistance. Insulin also regulates acetylcholine
synthesis (Kimura et al. 2016), thus possibly affecting
cognitive functions in dementia. Insulin resistance reduces
the amount of insulin that crosses the blood–brain barrier
(BBB), which hinders its role in the brain (see details in
glycemic control). It has been found that prolonged
hyperinsulinemia induces an impaired response to insulin
through decreased expression of insulin receptors at the
BBB and brain and consequently inhibits the insulin
transport into cerebrospinal fluid (CSF) and brain tissues
(Neumann et al. 2008). These changes could cause deficits
in learning and memory formation, probably due to a
neuroglial energy crisis (Kimura 2001, 2016; Craft et al.
1998). Higher levels of plasma insulin provoke amyloid
accumulation by limiting the degradation of Ab by direct
competition for the insulin degrading enzyme (IDE), which
degrades both insulin and Ab (Neumann et al. 2008).
However, lower insulin levels in CSF and the impaired
response to insulin and insulin-like growth factor-1 inhibit
the transportation of these carrier proteins and decrease the
clearance of Ab (Craft and Watson 2004). Third, chronic
exposure to hyperglycemia in DM also induces abnor-
malities in the cerebral capillaries (termed ‘‘vasculopenia’’)
(Serlin et al. 2011). Recent human study in asymptomatic,
late middle-aged adults (N = 186) from the Registry for
Alzheimer’s Prevention who underwent [C-11]Pittsburgh
compound B (PiB) position emission tomography as an
indicator of amyloid deposition in the brain tested the
interaction between insulin resistance and glycemic status
on PiB distribution volume in the cerebral cortex (Willette
et al. 2015a). The results of that study demonstrated that in
normoglycemia, higher peripheral insulin resistance cor-
responded to higher PiB uptake in frontal and temporal
areas, indicating that in individuals at risk for AD,
peripheral insulin resistance may contribute to and predicts
brain amyloid deposition in brain regions affected by AD.
Since this association was not confirmed in a much smaller
study on 47 participants (Thambisetty et al. 2013), further
studies are needed to resolve the nature of the link between
insulin resistance/T2DM and amyloid load. On the other
hand, peripheral insulin resistance has been found to pre-
dict MCI progression to AD, as shown by the study of the
Alzheimer’s Disease Neuroimaging Initiative which
included 194 MCI, 60 AD, and 26 cognitively normal
subjects (Willette et al. 2015b). The results suggested that
during the MCI stage, the homeostatic model assessment of
insulin resistance (HOMA-IR) as an index of peripheral
insulin resistance is differently associated with either hypo-
or hyper- glucose (FDG-PET) metabolism in different
brain areas, depending on whether participants progress to
develop clinical AD. Therefore, evidence accumulated
showing that peripheral insulin resistance, which is often
associated with a metabolic syndrome and T2DM, has a
role in prediction of AD pathology development, but its
most specific AD correlates have not been clearly defined
yet.
Finally, severe hypoglycemia may be also a risk factor
for cognitive impairments in patients with DM. It has been
reported that patients with recurrent severe hypoglycemic
episodes have a 1.5–2.0 times greater risk of the develop-
ment or deterioration of cognitive impairment (Thacker
et al. 2011). These are, however, prospective studies, and
as cognitive impairment is a long process, it is hard to
delineate the direction of the relationship, i.e., does cog-
nitive impairment cause severe hypoglycemia or does
severe hypoglycemia cause dementia. Older patients are
thought to have less brain reserve or brain plasticity than
younger patients (Artola et al. 2002). Therefore, it is
plausible that hypoglycemia could cause neurologic chan-
ges that render an older patient more susceptible to
dementia.
Glycemic control
Peripheral insulin of pancreatic origin crosses the BBB in a
tightly controlled manner, as the BBB expresses insulin
receptors, which may decrease in number in response to
specific conditions associated with chronic hyperinsuline-
mia and insulin resistance (Banks 2004; Banks 2006;
The diabetic brain and cognition
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Unger et al. 1991). At the level of the BBB, there is a tight
relationship between the presence of insulin receptors and
the topographic expression of glucose transporters partic-
ularly abundant in medial temporal lobe and diencephalic
structures, which notably are related to neurocognitive
functions (White 2002; Zhou et al. 2001), suggesting an
important role of insulin in modulation of glucose uptake
and utilization (Banks 2004; Baker et al. 2011; Craft et al.
2012; Hertz et al. 1981). Insulin stimulation of glucose
transporter-4 (GLUT4) seems to be critical to the regula-
tion of neuronal metabolism and the generation of energy
needed for memory and other neurocognitive functions.
The presence and functional activity of major insulin signal
transduction molecules in human primary astrocytes has
also been demonstrated, including glycogen formation and
cell proliferation, thus supporting neurons with energy,
since neurons cannot store glycogen for their own activity
(Heni et al. 2011).
A growing body of evidence points to the importance of
a condition of the insulin inability to serve its physiological
function in the brain, in literature described by two alter-
native terms, ‘‘brain insulin resistance’’ (BIR) (Su et al.
2017; Talbot et al. 2012; de la Monte et al. 2012) or ‘‘in-
sulin resistant brain state’’ (IRBS) (Correia et al. 2013;
Frisardi et al. 2010; Plaschke et al. 2010a, b; Salkovic-
Petrisic et al. 2009). At the molecular level, BIR is char-
acterized by a reduced response to insulin signalling gen-
erally downstream the insulin receptor (IR)—insulin
receptor substrate (IRS)—phosphatidyl inositol kinase-3
(PI-3) pathway in the brain, which, particularly considering
the neurotrophic, neuroprotective, and neuromodulatory
roles of brain insulin, may lead to neurodegeneration and
cognitive impairment as seen in AD as well as metabolic
alterations in hypothalamic functions, as seen in obesity
and T2DM (Kullmann et al. 2016). Although some authors
proposed that it might be considered as type 3 diabetes (de
la Monte and Tong 2014), others strongly disagree (Talbot
2014; Talbot and Wang 2014). BIR actually represents a
brain-related metabolic syndrome associated with meta-
bolic and oxidative stresses and neuroinflammation in the
brain, which may or may not be accompanied by alter-
ations in peripheral metabolic homeostasis, since T2DM
increases the risk for AD (and vice versa), but neither all
T2DM patients develop AD (and vice versa) nor AD is
necessarily associated with hyperglycemia (Talbot 2014;
Talbot and Wang 2014; Bla´zquez et al. 2014).
A clinical study on 30 normal, 29 MCI, and 30 AD
patients (Talbot et al. 2012) demonstrated that cognition
was negatively associated with levels of candidate bio-
marker of BIR serin-phosphorylated insulin receptor sub-
strate-1 (IRS-1 pS616) in the hippocampus, and that
association of episodic memory and IRS-1 pS616 was
statistically independent of Ab plaques, suggesting that
BIR is mechanistically closer than the plaques to the
molecular causes of cognitive decline in AD. A very recent
longitudinal, 35-month study in 57 MCI and 64 cognitively
unimpaired controls confirmed the existence of the inter-
action between insulin resistance-related genetic poly-
morphisms (AKT2, PIK3CB, IGF1R, PIK3CD, MTOR,
IDE, AKT1S1, and AKT1) and cognitive impairments in
MCI subjects, providing in vivo evidence that pathway of
BIR modifies cognitive performance, further showing that
the influence occurred in the absence of diabetes (Su et al.
2017).
Insulin resistance impairs the normal activity of the
brain; both experimental, imaginistic, and clinical non-in-
terventional studies have identified correlations between
insulin and cognitive functions—in particular impaired
memory and AD but also increased insulin resistance in a
significant number of patients with other neurodegenera-
tive diseases (de Felice et al. 2014; Craft et al. 2012; de la
Monte et al. 2012; Craft and Christen 2010; Ro¨nnemaa
et al. 2008; de la Monte et al. 2009). These implications
could be related to the role of insulin in the normal APP
and Ab cellular synthesis and processing, but also in the
brain-liver metabolic axis (de la Monte et al. 2012; de la
Monte 2009; Banks et al. 2012; Craft et al. 2013; Gasparini
and Xu 2003; Lin et al. 2000; Matsuzaki et al. 2010;
Passafaro et al. 2001; Sagare et al. 2012; Tamaki et al.
2007; Lopez et al. 2011). The role of brain insulin in the
control of the turn-over of Ab is also important for mixed
and vascular cognitive impairment as there is a tight
interference between the brain vascular risk factors and Ab
(as recently stated by AHA/ASA based on a significant
number of published research data) (Gorelick et al. 2011).
In addition, insulin has been shown to regulate the
phosphorylation of tau proteins (Rudolph et al. 2016).
Hyperphosphorylated tau contributes to the formation of
neurofibrillary tangles (Kimura 2016). It is also reported
that there are genomic/transcriptomic links between AD
and DM by meta-analysis study (Mirza et al. 2014).
A neuropathological evaluation of glucose/insulin-re-
lated molecules in AD, DM and controls is presented in
Table 1. These molecular post-mortem brain data agree
with histological and clinical studies underlying the
importance of glucose/insulin pathology as risk factors for
cognitive dysfunction. These results point to a concomitant
occurrence of alterations in the energy metabolism
pathways.
Considering the dysfunction of the brain insulin system
found in AD patients post-mortem (Luchsinger 2012), an
experimental rat model, the STZ-ICV model, which mir-
rors an insulin resistant brain state, seems to be an appro-
priate animal model for AD (Salkovic-Petrisic et al. 2009;
Luchsinger 2012; Hoyer 1998, 2004; Israili 2011; Gru¨n-
blatt et al. 2007; de la Monte 2009).
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Table 1 Neuropathological evaluation of glucose transporter, insulin/insulin receptor, and its related molecules in AD compared to T2DM and
controls
Parameter Pathological
group (n)
Brain region Results Reference
O-GlcNAcylation
GLUT3
Tau phosphorylation
Control (n = 7)
T2DM (n = 11)
AD (n = 10)
T2DM ? AD
(n = 8)
Frontal cortices ; O-GlcNAcylation
Glucose vs. Ct
; GLUT3 vs. Ct (higher extent in
T2DM)
: Tau-p vs. Ct (in AD and in some
tau epitopes in T2DM)
Liu et al.
(2009)
Ab plaques
AGEs
RAGE
Tau
Control (n = 9)
DM (n = 3)
AD (n = 10)
AD ? DM
(n = 9)
Cerebellum, hippocampus and cerebral
cortex (temporal, frontal and parietal
lobes)
: Ab plaques vs. Ct and DM
: AGEs vs. Ct and DM
: RAGE vs. Ct (in particular in
AD ? DM) hilar cells
: Tau aggregates vs. Ct and DM
(in particular in AD ? DM)
Valente et al.
(2010)
IRb
Phosphorylated PPARc
Control (n = 9)
AD (n = 10)
T2DM (n = 10)
AD ? T2DM
(n = 10)
Frontal cortex, dorsal and ventral
hippocampus
; IRb cortex vs. Ct, T2DM and
AD ? T2DM
; IRb hippocampus vs. Ct
: p-PPARc vs. Ct
Bartl et al.
(2012)
Ceramide (activates insulin
resistance)
Control (n = 8)
Moderate AD
(n = 8)
Advanced AD
(n = 8)
Anterior frontal lobe : Ceramide in advanced AD de la Monte
et al.
(2012)
Insulin stimulation ? IR, IRS-
1, PI3K, IGF-1R and IRS-2
Control (n = 8)
AD (n = 8)
Cerebral cortex, hippocampal formation ; Insulin response IR, IRS-1,
PI3K, IGF-1R and IRS-2 vs. Ct
Talbot et al.
(2012)
IRb-pY960
IRS1
IRS1-pY612
IRS1-pY941
IRS1-pY312
IRS1-pS616
IRS1-pS636/639
PIP3
GSK3b
mTOR-pS2448
Control (n = 30)
MCI (n = 29)
AD (n = 31)
Hippocampal CA1 ; IRb-pY960 in AD
; PIP3 and GSK3b vs. Ct
: IRS1, IRS1-pS616 and IRS1-
pS636/639 vs. Ct
: IRS1-pY612, IRS1-pY941, IRS1-
pY312 and mTOR-pS2448 in AD
Talbot et al.
(2012)
Ab
HNE
AGE
Insulin
GLP-1
PYY
Leptin
Control (n = 8)
Moderate AD
(n = 8)
Advanced AD
(n = 8)
Frontal lobe : Ab and HNE in Advanced AD
: AGE vs. Ct
; Insulin, GLP-1 and PYY in
advanced AD
: Leptin in advanced AD
Lee et al.
(2013)
IRS1-pS616
IRS1-pS312
Akt-pS473
Control (n = 25)
AD (25)
Tauopathy
(n = 38)
a-synucleinopathy
(n = 41)
TDP-43
proteinopathy
(n = 28)
Midfrontal gyrus, angular gyrus,
hippocampus
: In AD and slightly in tauopathies Yarchoan
et al.
(2014)
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Brain insulin resistance (BIR) as a shared
pathological feature in obesity, cardiovascular
disease, T2DM, and dementia
Evidence has gathered suggesting that BIR seems to be a
shared pathological feature of metabolic and cognitive
disturbances in T2DM, obesity, cardiovascular disease, and
dementia patients (Kullmann et al. 2016; Lutski et al.
2017), which may provide the missing link between these
disorders. Indeed, recent evidence suggests that insulin
resistance is related to subsequent poorer cognitive per-
formance and greater cognitive decline among patients
with cardiovascular disease with and without diabetes
(Lutski et al. 2017). Clinical investigation of the link
between the obesity and BIR showed that obese men
respond to cognitive but not to catabolic brain insulin
signalling (Hallschmid et al. 2008), indicating that not all
insulin activities in the brain have been equally affected by
BIR and that insulin resistance in metabolic disorders does
not uniformly affect all target cells and intracellular sig-
naling pathways in the brain (Ko¨nner and Bru¨ning 2012).
Whereas dementia predominately affects cognitive target
regions of insulin action, T2DM- and obesity-associated
BIR predominately targets hypothalamic insulin action, but
there is overlap of these three disorders in impairment of
functional connectivity in prefrontal and lateral temporal
cortices and hippocampus as reviewed by Kullmann et al.
(2016). Thus, numerous clinical phenotypes may arise from
selective insulin resistance, leading to inhibition of defined
intracellular signaling pathways in some tissues, while in
other cell types, insulin action is maintained or even
overactivated (Ko¨nner and Bru¨ning 2012). Furthermore,
magnetoencephalographic studies on carriers of obesity-
and diabetes-risk genes (fat-mass and obesity-associated
gene/FTO/and IRS-1, respectively) showed an attenuated
insulin-mediated response in the brain (Tschritter et al.
2006, 2007). In lean humans, insulin infusion modulates
cerebrocortical activity as demonstrated by magnetoen-
cephalography, while these effects are suppressed in obese
individuals, indicating lower cerebrocortical response to
insulin, i.e., BIR in this particular region, found in indi-
viduals with the Gly972Arg polymorphism in IRS-1, a
T2DM risk gene (Tschritter et al. 2006). The same group
demonstrated also that variation in the FTO gene locus
(obesity-risk gene) is associated with cerebrocortical
insulin resistance, but in these subjects, the effect of FTO
polymorphism was independent of the Gly972Arg poly-
morphism in IRS-1 (Tschritter et al. 2007). These studies
clearly indicate that each genetic determinant for BIR
involves different neuronal systems (Kullmann et al. 2016),
which may provide an explanation why AD is associated
with T2DM in some, but not all demented patients, and
vice versa, why T2DM is associated with AD in some but
not all diabetic patients.
BIR is not necessarily a secondary pathological event as
mentioned earlier in the text (references Neumann et al.
2008; Kimura 2001, 2016; Craft et al. 1998; Craft and
Watson 2004). Considering the BIR as a shared feature in
obesity, T2DM, and dementia, etiology of BIR as a primary
pathological event could be related to the maternal envi-
ronment during pregnancy and its influence on the fetus,
according to the studies showing that the change of insulin
action in fetuses of diabetic mothers influences the fetal
brain (Sobngwi et al. 2003). Intrauterine exposure of
fetuses to a non-physiological concentration of insulin
during critical periods of early development can lead to a
permanent malprogramming of fundamental regulatory
systems including those in hypothalamus, as demonstrated
Table 1 continued
Parameter Pathological
group (n)
Brain region Results Reference
IRS1-pS616
IRS1-pS636/639
IRS1-pY612
Control (n = 3)
AD (n = 3)
Temporal cortex, hippocampus ; IRS1-pS616 nucleus stains vs. Ct
; IRS1-pS636/639 nucleus stains vs.
Ct
; IRS1-pY612 nucleus stains vs. Ct
Garwood
et al.
(2015)
Ab
Autophagy (Beclin-1 and LC-
3)
PI3K/Akt/mTOR
Phosphatase
Tensin homolog
IRS1
GSK3b
Control (n = 8)
Late AD (n = 8)
Amnestic MCI
(n = 8)
PCAD (n = 8)
Inferior parietal lobule : Ab with ; autophagy vs. Ct
: PI3K/Akt/mTOR in MCI and
AD vs. Ct
; Phosphatase and tensin in MCI
and AD vs. Ct
: IRS1 and GSK3b in MCI and
AD vs. Ct
Tramutola
et al.
(2015)
GLUT3 glucose transporter 3, Ct control, AD Alzheimer’s disease, T2DM type 2 diabetes mellitus, AGEs advanced glycation end products,
RAGE receptor for AGEs, DM diabetes mellitus, IRb insulin receptor subunit b, IRS1 insulin receptor substrate-1, MCI mild cognitive
impairment, PCAD pre-clinical AD, HNE 4-hydroxynonenal
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for elevated insulin level during perinatal life which pro-
grammed the development of obesity and diabetes
(Plagemann 2008). Recent meta-analysis of 19 studies
including 2260 subjects has confirmed a strong support for
the fetal programming hypothesis (Pearson et al. 2015). It
is not only stress that might be a confounding factor, as the
effects of chronic exposure to stress hormones on cognition
at different stages in life including the prenatal age, depend
on the brain areas that are developing or declining at the
time of exposure (Lupien et al. 2009). Therefore, envi-
ronmental factors and epigenetic mechanisms operating
during pregnancy and postnatally may affect particular
susceptibility genes and stress factors, consequently
affecting brain development and causing respective dis-
eases like AD and/or T2DM that manifest late in life when
aging takes place and may become a trigger of desyn-
chronization of biological systems (Salkovic-Petrisic et al.
2009).
Cerebral blood flow
Age-related dysfunction based on reduced capillary func-
tion declines in uptake of energy metabolites, amino acids,
trophic factors, and other metabolic constituents, is of
eminent importance in a variety of brain-related disorders
(Kang et al. 2017; Bellou et al. 2017). T2DM favours such
age-dependent dysfunction and potentiates energy loss in
brain tissue. Therefore, aging eventually combined with
stress, which per se exerts negative effects on T2DM, is
both potential risk factors for AD (de Matos et al. 2017).
While under physiological conditions, compensatory
mechanisms are able to keep the homeostasis of brain
nutrition for a long time, chronic dysfunction finally will
overcome compensatory functions leading to neuronal
death.
Glucose-6-phosphate dehydrogenase plays a pivotal role
in homeostatic redox control by providing reducing
equivalents to glutathione, the major non-enzymatic cel-
lular antioxidant. As OS plays an important role in the
pathogenesis of AD, it is noteworthy that both glucose-6-
phosphate dehydrogenase and sulfhydryl concentrations
are upregulated in AD, showing compensatory regulation.
According to an alternative two-hit vascular hypothesis,
Ab accumulation in the brain is a second pathology (hit 2)
initiated by vascular damage (hit 1; Fig. 1). Neurovascular
dysfunction and hypoperfusion/hypoxia can reduce Ab
vascular clearance across the BBB and increase Ab pro-
duction from Ab precursor protein (APP), respectively,
causing Ab accumulation in the brain. Elevated levels of
Ab in the brain may in turn accelerate neurovascular and
neuronal dysfunction and promote self-propagation, lead-
ing to cerebral b-amyloidosis (Sagare et al. 2012).
Chronic brain hypoperfusion (CBH) can be present for
many years without eliciting mental symptoms, creating
instead an insidious neuronal energy crisis that is finally
expressed by progressive cognitive deficits in affected
individuals.
In this scenario, the presence of advanced aging plus
vascular risk factors can lower cerebral perfusion by
inducing any of number of abnormal hemodynamic
mechanisms affecting blood pressure, vessel patency,
vascular wall shear stress, blood flow resistance, blood
viscosity, and chemical blood flow regulators (Blennow
et al. 1990).
As neurons have no energy reserves, the performance of
cognitive tasks is critically dependent on the steady
delivery of adequate oxygen and glucose to produce ade-
nosine triphosphate (ATP). This nutrient delivery is inad-
equate in the aging brain.
Diminished CBF, neurovascular dysfunction, and
impaired vascular clearance of Ab from brain support an
essential role in linking DM and AD pathogenesis (de la
Torre 2010).
The glymphatic system mediates clearance of the
interstitial solutes in the brain by exchange of cerebrospinal
and interstitial fluids (CSF and ISF). The glymphatic sys-
tem consists of CSF influx from the paravascular space of
cerebral arteries, ISF clearance along the para-venous
space and the astroglial water channel AQP4 that partially
mediates transparenchymal changes of CSF and ISF (Iliff
et al. 2013; Yang et al. 2013). Impairment of the glym-
phatic system induces accumulation of Ab (Iliff et al. 2013;
Yang et al. 2013). Using a rat model of DM induced by
nicotinamide and STZ, Jiang et al. (2016) showed that
compared to age matched non-diabetic rats, middle-aged
DM rats exhibited spatial learning deficits. An odour
recognition test which detects non-spatial memory deficits
showed that DM rats failed to form new memories. In vivo
dynamic Gd-DTPA contrast-enhanced MRI analysis con-
firmed by ex vivo confocal image analysis indicated that
DM impairs the glymphatic system that mediates clearance
of the interstitial solutes in the brain (Jiang et al. 2017).
Cognitive deficits were highly and inversely correlated to
the impairment of the glymphatic system. Immunohisto-
logical analysis showed the presence of microvascular
leakage and loss of AQP4, axons, and oligodendrocytes in
the hippocampi of DM rats (Hamed 2017).
Inflammation in the diabetic brain
It has been shown clinically that disturbances of the BBB
play a role in the development of AD, especially in elderly
patients (Blennow et al. 1990). Therefore, peripheral
inflammatory factors from DM could leak to the brain
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parenchyma and induce activation of microglial cells to
release inflammatory molecules (Breteler 2000), thus
contributing to the pathophysiology of AD and VaD. There
have been studies which have pointed out that inflamma-
tory pathways may be acting as a possible mechanistic link
between the two disorders. Takeda et al. (2010, AD and
VaD) crossed transgenic mice (APP23) with diabetic mice
(ob/ob) and looked at the metabolism and pathology of the
brains in those double mutant mice (APP?-ob/ob). AD-
like cognitive impairment was observed in APP?-ob/ob
mice. Cerebrovascular inflammation, severe cerebral
amyloid angiopathy, and up-regulation of RAGEs were
observed in those double mutant mice even before the
appearance of cerebral amyloid angiopathy, suggesting
their role in cognitive impairment (Takeda et al. 2010).
These findings agree with pathology of the cerebral vas-
culature in AD and DM (Blennow et al. 1990; Breteler
2000).
Oxidative stress (OS) caused by chronic hyperglycemia
in chronic experimental diabetic neuropathy has been
shown to cause oxidative injury of dorsal root ganglion
neurons, specifically damaging the mitochondrial function
and neuronal cell death (Schmeichel et al. 2003).
Prolonged metabolic stress conditions could be activated
by various cell stressors, as hypoxia, oxidative stress, viral
infections, and trophic withdrawal or various insults unveil
deleterious effects of p53-evoked insulin resistance in
neurons; enhancement of transcription of pro-oxidant fac-
tors, accumulation of toxic metabolites (AGE and ROS)-
modified cellular components, together with activation of
proapoptotic genes, could finally move a suicide death
program of autophagy/apoptosis in neurons. The important
role of p53 driving insulin resistance in AD brains validates
attempts to inhibit p53 activity in neurons, since it could
promise an improvement of the disease therapy. Recent
studies reveal the impact of p53 on expression and pro-
cessing of several microRNA (miRs) under DNA damage-
inducing conditions. In addition, the role of miRs in pro-
motion of insulin resistances and in T2DM has been well
documented. Detailed recognition of the role of p53/miRs
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Fig. 1 Vascular hypothesis of
Alzheimer disease. HIT 1
Vascular damage as primary
pathological event. HIT 2 Ab
accumulation as secondary
pathological event. Modified
from Sagare et al. (2012) (This
copyright agreement is admitted
by describing Cold Spring Herb
Perspect Med 2012;2:a011452)
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crosstalk in driving insulin resistance in AD brains could
improve the disease diagnostics and future therapy
(Vousden 2010).
The kynurenine pathway, the main metabolic route of
tryptophan degradation, produces several neuroactive
molecules [such as the excitotoxin antagonist kynurenic
acid (KYNAC) and the excitotoxin quinolinic acid (QA)].
Alterations in the kynurenine pathway may promote glu-
tamate-mediated excitotoxic neuronal damage and inflam-
matory processes (Vecsei et al. 2013). Recently, it was
shown that STZ-induced experimental T1DM increases
hippocampal content of KYNAC (Chmiel-Perzynska et al.
2014). The increased KYNAC level may have negative
impact on cognition. KYNAC in the course of DM could
be associated with an enhanced ketone body formation. In
cortical slices and glial cultures, beta-hydroxybutyrate
(BHB) augments KYNAC production by stimulating KATs
activity in the protein kinase-A dependent way, thus
explaining the neuroprotective actions of BHB (Chmiel-
Perzynska et al. 2011).
Potential role of butyrylcholinesterase in linking
diabetes and cognitive dysfunction
In AD, the brain levels of AChE go down, while those of
BChE (the protein butyrilcholinesterase) go up, resulting in
a dysregulation causing cholinergic deficit. As levels of
that enzyme are altered in T2DM too, those authors suggest
a synergistic negative interaction of T2DM and AD on
cholinergic neurotransmission (Mushtaq et al. 2014).
Among common pathogenic factors between DM and AD,
BChE has been studied in vitro and in plasma (Sridhar
et al. 2006; Rao et al. 2007; Shaikh et al. 2014). Alterations
in the level of plasma BChE occur in DM; variant forms of
the plasma enzyme occur in both DM and AD (Sridhar
et al. 2010; Raygani et al. 2004). In vitro studies demon-
strate a common pathogenic mechanism (Sridhar et al.
2006; Diamant et al. 2006). Whereas brain hyperglycemia
mediates hippocampal neuron responses (Macauley et al.
2015), BCHE levels also correlate with cerebral glucose
metabolism and cerebral Ab load (Darreh-Shori et al.
2011). BChE associates particularly with the malignant
form of Ab plaques, suggesting its role in transforming
non-fibrillar to the malignant fibrillar form (Reid and
Darvesh 2015). To account for a gender difference, a gene–
gene interaction between BChE and estrogen-associated
genes was proposed (Reid and Darvesh 2015). However,
the relation between BChE and AD is not settled yet. While
an earlier meta-analysis of the K-Variant of BChE sug-
gested that it was related to development of AD in Asians
(Want et al. 2015), but a more comprehensive meta-anal-
ysis failed to confirm the relation (Ji et al. 2015).
T2DM is not only associated with an increased risk of
cognitive decline and different types of dementia but also
with cerebrovascular and peripheral vascular disease
(Hoyer et al. 1999; Hoyer 1998, 2004; Israili 2011).
Moreover, cerebrovascular disease may contribute to the
severity of cognitive decline in AD (Last et al. 2007).
For the group, it is evident that disruption of glucose
metabolism in both AD and VaD is based on multiple
triggers. However, there is no agreement on follow-up and
time-course of pathological cascade.
Imaging the diabetes–cognitive impairment
relationship
Rapid advances in neuroimaging have confirmed a link
between cognitive impairment and poor metabolic control
in DM, mediated by the structural and functional brain
changes (van Bussel et al. 2017). Whole-brain analysis
revealed a consistent link between DM and brain atrophy
and this atrophy is often more pronounced within the
hippocampus (Gold et al. 2007). However, a pooled anal-
ysis of three cohort studies showed that the degree of
hippocampal atrophy in T2DM is comparable to the degree
of total brain atrophy (Biessels et al. 2006a, b). Brain
atrophy in T2DM is associated with poor cognition, pre-
dominantly attention and executive function, and infor-
mation-processing speed and memory (Moran et al. 2013;
van Elderen et al. 2010; Manschot et al. 2006).
Whole-brain grey matter (GM) atrophy may be associ-
ated with T2DM; the association is more convincing for
regional GM atrophy (Gold et al. 2007; Last et al. 2007).
Similarly, the association of global and regional white
matter (WM) atrophy and WM hyperintensities with DM
was not consistently reported (Friedman et al. 2014).
T2DM is clearly associated with the occurrence of lacunes
(van Harten et al. 2007).
Functional magnetic resonance imaging (fMRI)
demonstrated reduced synchronized activity within default
mode network in cognitively normal T2DM patients
(Musen et al. 2012). Regional basal cerebral blood flow
(CBF) and cerebrovascular reactivity (CVR) have been
shown to be decreased in T2DM patients (Zlokovic 2008).
Longitudinal studies have confirmed the association of
CBF and CVR with cognitive function and total brain
volume in T2DM at baseline. However, both indexes of
cerebral hemodynamics have not been predictive for atro-
phy and cognitive decline, and seem to be secondary
phenomena (Brundel et al. 2012).
Neuroimaging studies may serve as early biomarkers
and as monitors of progression of cognitive impairment in
subjects with DM (Moran et al. 2015). Several methods
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have been attempted to identify anatomical and
biomolecular markers linking accelerated cognitive decline
with insulin resistance. First, MRI studies have consistently
shown that chronic hyperglycemia is associated with brain
atrophy and cerebrovascular lesions (Moran et al. 2013;
van Bussel et al. 2017), which are hallmarks of attention
deficits and impaired executive functioning (McCrimmon
et al. 2012). There is no consensus on the exact mechanism
of neurodegeneration leading to accelerated cognitive
decline in DM and whether it is mediated by neuronal
atrophy or/and cerebrovascular lesions (Biessels 2013).
Such uncertainty undermines MRI as an early predictive
tool for the transformation potential of MCI into AD in
normal as well as DM subjects. For example, the AD
Neuroimaging Initiative (http://www.adni-info.org/) has
been validating the use of MRI/PET imaging for the pre-
diction of MCI-to-dementia conversion within 18 months
of diagnosis. Patients who converted to dementia showed
changes in GM volume, amyloid deposition, and glucose
metabolism in multiple regions compared with those who
did not develop dementia. In a recent analysis of the data
collected using structural MRI, amyloid-PET and 18F-
FDG-PET scans, investigators could predict the transition
with maximum accuracy of 72% (Teipel et al. 2015). In
addition to its low predictive potential, this approach can
only provide circumstantial clues on the underlying
mechanism of accelerated cognitive decline leading to AD
and dementia in DM patients.
In addition, DM triggers molecular alterations that elicit
deranged microvascular and mitochondrial functions,
increased inflammation, and elevated levels of advanced
glycation end products (AGEs) (Kim et al. 2012; Goldin
et al. 2006). All these diverse pathways converge at a nodal
point where positive feedback loops exacerbate OS which
is invariably implicated in neurotoxicity, neurodegenera-
tion, and cognitive deficits. It can be suggested, therefore,
that biomarkers of OS may provide early predictive probes
for cognitive decline in DM subjects (Pratico` et al.
2000, 2002; Keller et al. 2005; Aluise et al. 2011; Baldeiras
et al. 2010; Thomas et al. 1996).
The group concluded that imaging studies (MRI, PET)
contribute to an early diagnosis of AD and VaD. However,
specificity and selectivity do not reach sufficient levels to
be used solely for a precise clinical diagnosis.
Pathology
Both T1DM and T2DM induce regional microstructural
changes in cortical and subcortical brain structures that are
associated with impairment of neurocognitive functions
(Seaquist 2015). Some autopsy studies stated that patients
with DM have significantly less AD pathology but more
frequent cerebrovascular lesions including microvascular
changes (Alafuzoff et al. 2009; Beeri et al. 2005; Nelson
et al. 2009; Ahtiluoto et al. 2010) or both types of cerebral
pathology (Alafuzoff et al. 2009; Vagelatos and Eslick
2013; Ahtiluoto et al. 2010; Takeda et al. 2011; Verdile
et al. 2015), and white matter lesions (Jellinger 2015a, b).
The increased risk of cognitive decline in elderly subjects
with DM is due to dual pathology, involving both the CVD
and cortical atrophy (Biessels et al. 2006a, b; Umegaki
2012). Two different patterns of cerebral injury were seen
in patients with dementia depending on DM status: greater
amyloid plaque load in untreated DM patients but more
frequent deep microvascular infarcts in those with treated
DM (Sonnen et al. 2009). Central vascular disease and
exacerbated pathology were seen in a mixed model of DM
and AD by crossing APP/PS1 mice (AD model) with db/db
mice (DM model) that show an age-dependent synergistic
effect between DM and AD, including brain atrophy, senile
plaques, hemorrhagic burden, and increase of microglia
activation (Ramos-Rodriguez et al. 2015). Insulin resis-
tance, hyperinsulinemia, and hyperglycemia can promote
the onset of AD (Ro¨nnemaa et al. 2008; de Oliveira Lanna
et al. 2014) by accelerating tau phosphorylation and neu-
ritic plaque formation (Bitel et al. 2012; Matsuzaki et al.
2010) and, overlapping with AD pathology, aggravate the
progression of neurodegeneration due to OS, mitochondrial
dysfunction, neuroinflammation, etc. as a common back-
ground (Carvalho et al. 2015; Kraska et al. 2012; Roriz-
Filho et al. 2009; Rosales-Corral et al. 2015). Thus,
impaired insulin signaling may be a possible link between
AD and DM (Jellinger 2015a, b; Sato et al. 2011).
Although insulin mitigates Ab deposition and phosphory-
lation of tau (Bedse et al. 2015), DM in combination with
APOEe4 may lead to excessive hyperphosphorylation of
tau (Matsuzaki et al. 2010) and exacerbation of AD
pathology (Malek-Ahmadi et al. 2013). However, a very
recent publication (Abner et al. 2016) concludes that dia-
betes is associated with cerebrovascular but not AD
pathology.
An extensive literature search reviewing 275 publica-
tions reporting post-mortem brain analyses of AD and VaD
and published between 1980 and 1994 was performed
(Gsell et al. 1996). In comparison to AD, in VaD, human
brain neurotransmitter alterations are mild, e.g., for choline
acetyltransferase activity, muscarinic receptor density,
serotonin, dopamine, homovanillic acid, dopamine D1-and
D2-receptor density, noradrenaline, and gamma aminobu-
tyric acid (GABA), while 5-hydroxyindoleacetic acid (5-
HIAA) shows a more pronounced deficiency. This data
summarized here agree in principle with more recent
conclusions of post-mortem human brain studies and
experimental models (Ohara et al. 1994; Pimlott et al.
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2004; Jia et al. 2004; Tohgi et al. 1996; Chen et al. 2013;
Lee et al. 2014; Niwa et al. 2002; Pedro´s et al. 2014;
Knezovic et al. 2015; Barilar et al. 2015). CSF concen-
trations of choline were significantly higher in VaD
patients compared to AD and controls but did no correlate
with mini-mental state examination (MMSE) scores (Jia
et al. 2004; Tohgi et al. 1996).
It is evident for the group that the pathology of AD and
VaD shows multiple alterations at both neuropathological
and neurochemical levels. In addition, mixed-type
dementia pathology is frequent.
Animal models
There are few literature data on brain insulin resistance
(BIR) and glucose hypometabolism in widely exploited
transgenic AD mice models in which amyloid/tau-related
gene manipulation is an inevitable starting point as ante-
cedent to BIR allowing thus no clear conclusion on BIR–
cognition relationship (Chen et al. 2013; Lee et al. 2014;
Niwa et al. 2002; Pedro´s et al. 2014), which contrasts
animal treated intracerebroventricularly with STZ (non-
transgenic STZ-icv model). STZ-icv administration indu-
ces dysfunctional insulin receptor signalling and mirrors
the etiology of AD and in part that of cerebrovascular
diseases (Table 2). Two long-term follow-up studies of
STZ-icv rat model which provided the first staging of
cognitive, structural/ultrastructural, neuropathological, and
BIR markers in the STZ-icv rat model showed that cog-
nitive deficit correlated well with GSK-3b activity (larger
deficits–higher activity) and IDE protein expression (larger
deficits–lower expression), in a bi-phasic time-dependent
manner, with cognitive deficits becoming manifested later
than dysfunctions in brain insulin system (Knezovic et al.
2015; Barilar et al. 2015). AD-like structural pathology
seen in STZ-icv rat model in the form of early neurofib-
rillary changes and Ab accumulation becomes manifested
later than insulin- and memory-related changes and follows
slow, graduating progression (Knezovic et al. 2015).
Findings in this non-transgenic sAD animal model strongly
support clinical data indicating BIR as a possible primary
pathological event in AD development. Furthermore,
recently developed and thus far less explored STZ-icv
mokey model demonstrates BIR (Lee et al. 2014) accom-
panied by Ab deposition and tauopathy (Yeo et al. 2015),
while BIR induced by STZ-icv treatment aggravates cog-
nitive deficits and increases the formation of pathomor-
phological AD hallmarks, particularly Ab accumulation in
APP overexpressing (Plaschke et al. 2010a, b) and Prese-
nilin-1-Val97Leu mutant (Lin et al. 2014) transgenic mice
AD models.
Long-term drug testing polygon considering the pre-
liminary data of the therapeutic role of icv insulin in the
STZ-icv model (Shingo et al. 2013) and of intranasal
insulin in AD patients (Claxton et al. 2015) should be
performed to elucidate the importance of glucose/insulin
pathology as risk factor for both, AD and VaD.
The representative experiments (C3 mg/kg STZ-icv;
rat) demonstrate the following order of AD-like pathology
appearance: IRBS = oxidative stress = neuroinflamma-
tion[ glucose hypometabolism = tau pathology = cog-
nitive deficits[ amyloid b1-42 accumulation[ amyloid
angiopathy[ amyloid plaques. These data support possi-
ble causal role of IRBS in sAD etiopathogenesis (Chen
et al. 2014; de la Monte et al. 2014), confirmed by thera-
peutic effect of icv insulin in this model (Shingo et al.
2013) and intranasal insulin in AD patients (Claxton et al.
2015), and contributing role of vascular pathology in pro-
gression of cognitive decline as demonstrated in 9-month
follow-up studies of this model (Knezovic et al. 2015;
Salkovic-Petrisic et al. 2011).
IRBS is a condition characterized at the molecular level
by reduced response to insulin signaling downstream the
insulin receptor (IR)–insulin receptor substrate (IRS)–
phosphatidyl inositol kinase-3 (PI-3) pathway in the brain,
which, particularly considering the neurotrophic, neuro-
protective and neuromodulatory role of brain insulin (Craft
and Christen 2010; Gasparini and Xu 2003; Sato et al.
2011), may lead to neurodegeneration and cognitive
impairment as seen in AD. Although sometimes termed
‘‘type 3 diabetes’’ (de la Monte and Tong 2014), it actually
represents a brain-related metabolic syndrome associated
with metabolic and oxidative stress and neuroinflammation
in the brain, which may or may not be accompanied by
alterations in peripheral metabolic homeostasis, since
T2DM increases the risk for AD (and vice versa), but
neither all T2DM patients develop AD (and vice versa) nor
AD is necessarily associated with hyperglycemia (Talbot
and Wang 2014; Talbot and Wang 2014; Bla´zquez et al.
2014).
While animal models are referred to in other consensus
BMC-related manuscript, the group focused here on mod-
elling the IRBS. It is concluded that the icv STZ rodent
model mirrors AD and VaD pathologies in many respects.
The model should be used with or without combination of
transgenic mouse models.
Treatment of diabetes-related cognitive
impairment
Currently little is known regarding the effect of diabetes
interventions on diabetes-related cognitive impairment. The
ACCORD-MIND study conducted among *3000
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individuals with DM demonstrated that tight glycemic con-
trol significantly reduced the rate of brain atrophy over a
period of 20–40 months compared with the standard glucose
treatment; however, there was no difference between the
groups in the rate of cognitive decline as measured by 4
cognitive instruments (Cukierman-Yaffe et al. 2009).
Table 2 Cerebral amyloid angiopathy in the rat model of sporadic Alzheimer’s disease (sAD) induced by intracerebroventricular administration
of streptozotocin (STZ-icv) which generates insulin resistant brain state (IRBS) and dose- and time-dependent AD-like pathology
AD-like pathology
in rat
Time after C3 mg/kg STZ-icv treatment (months)
\0.5 C0.5 C1 C3 C6
Cognitive deficit - ? ? ? ?
Knezovic et al.
(2015)
Knezovic et al. (2015),
Agrawal et al. (2011)
Knezovic et al. 2015,
Kosaraju et al. (2013)
Knezovic et al.
(2015), Hoyer
et al. (1999),
Samy et al. (2016)
Knezovic
et al. (2015)
Tau pathology ND ? ? ? ?
Knezovic et al. (2015), Barilar
et al. (2015), Deng et al.
(2009a, b), Lester-Coll et al.
(2006)
Knezovic et al. (2015),
Barilar et al. (2015),
Kumar et al. (2010),
Lester-Coll et al. (2006)
Knezovic et al.
(2015), Barilar
et al. (2015)
Knezovic
et al.
(2015),
Barilar et al.
(2015)
Amyloid b1-42
accumulation
- - -/? ? ?
Knezovic et al.
(2015)
Knezovic et al. (2015) Knezovic et al. (2015),
Correia et al. (2013),
Kosaraju et al. (2013)
Knezovic et al.
(2015); Samy
et al. (2016)
Knezovic
et al. (2015)
Amyloid b1-42
plaques
- - - - ?
Knezovic et al.
(2015)
Knezovic et al. (2015) Knezovic et al. (2015) Knezovic et al.
(2015), Samy
et al. (2016)
Knezovic
et al. (2015)
Amyloid
angiopathy
ND ND -
Salkovic-Petrisic et al.
(2011)
Salkovic-Petrisic
et al. (2011)
Salkovic-
Petrisic
et al. (2011)
Insulin receptor
signalling
pathway
dysfunction
? ? ? ? ?
Barilar et al. 2015 Barilar et al. (2015), Sharma
and Gupta (2003), Agrawal
et al. (2011), Lester-Coll
et al. (2006)
Barilar et al. (2015), Du et al.
(2014)
Barilar et al. (2015) Barilar et al.
(2015)
Glucose
hypometabolism
ND ? ? ND ND
Hoyer and Lannert (2007),
Plaschke and Hoyer (1993)
Hoyer and Lannert (2007),
Plaschke and Hoyer (1993)
Cholinergic deficit ND ? ? ND ND
Kumar et al. (2010), Tota et al.
(2012)
De la Monte et al. (2006),
Sharma et al. (2010)
Oxidative stress ? ? ? ? ND
Shoham et al.
(2007),
Hassanzadeh
et al. (2015)
Shoham et al. (2007), Sharma
and Gupta (2003), Javed
et al. (2012)
Shoham et al. (2007) Deng et al.
(2009a, b), Samy
et al. (2016)
Neuroinflammation ? ? ? ND ND
Shoham et al.
(2007), Deng
et al. (2009a, b)
Shoham et al. (2007),
Rodrigues et al. (2009)
Shoham et al. (2007)
STZ-icv streptozotocin-intracerebroventricularly, AD Alzheimer’s disease, ND no data
? Change reported
- No changes found
?/- Inconsistent reports with changed or unchanged parameter
P. Riederer et al.
123
Analogue compounds for the incretin hormone GLP-1
(glucagon-like peptide-1), which facilitate endogenous
insulin release and are used to treat T2DM, reduce Ab
accumulation, and rescue impairments in hippocampal
synaptic plasticity and spatial learning memory in trans-
genic mouse models of AD (Gengler et al. 2012).
Many studies suggest that adding more insulin to the
brain would improve memory and prevent cell damage
(Shingo et al. 2013; Claxton et al. 2015). In individuals
without DM, it has been shown amongst cognitively intact
and cognitively impaired individuals that a form of insulin
that enters the brain selectively has beneficial effects on
some cognitive domains (Shemesh et al. 2012). In the
ORIGIN cognitive sub-study, treatment of people with DM
and prediabetes for 6.5 years with basal insulin had a
neutral effect on cognitive function (Cukierman-Yaffe
et al. 2014).
There is one interesting report on the use of bacterio-
phage as a common divergent therapeutic approach for
treating AD and T2DM (Sohrab et al. 2014). Invokana
(Canagliflozin), which has dual inhibitory effect on
acetylcholinesterase as well as on SGLT2, represents
advancement in the parallel management of AD and T2DM
(Rizvi et al. 2014). Galangin (a novel natural ligand) has
inhibition characteristics on human brain acetyl-
cholinesterase, butyrylcholinesterase, and 5-lipoxygenase
(Shaikh et al. 2014). Molecular interaction of human brain
acetylcholinesterase (target enzyme in AD therapy) has
also been studied with a natural inhibitor, Huperzine-B
(Alam et al. 2014a).
Elements such as magnesium play an important role in
the normal functioning of many enzymatic activities. There
has been some evidence for the role of magnesium in the
prevention and therapy of AD and T2DM (Gro¨ber et al.
2015), and there are some recent nanotechnological
approaches in the management of AD and T2DM (Alam
et al. 2014b).
Pantethine has beneficial effects in vascular disease,
is able to decrease the hyperlipidemia, moderates the
platelet function, and prevents lipid-peroxidation (Hor-
va´th and Ve´csei 2009). The disulfide group (oxidized
form of pantethine) is necessary to lower the platelet
response to activation by thrombin and collagen (Penet
et al. 2008). It was found that orally active multi-
functional antioxidants including pantethine delay cat-
aract formation in streptozotocin T1DM and gamma-
irradiated rats (Randazzo et al. 2011). Pantethine should
be considered for the treatment of lipid abnormalities
also in patients at risk such as those with DM and other
dementia disorders.
The possible implications of the relationship
between dementia/cognitive impairment
and diabetes on the care of the older individual
with diabetes
Current guidelines for treatment of individuals with DM
include extensive life style changes in diet, physical
activity, smoking cessation, medication, and routine med-
ical follow-up (Powers et al. 2015). To successfully man-
age self-care of such changes, the individual with DM is
required to have intact cognitive function; i.e., to under-
stand and learn new information, memorize it, apply new
behaviors and procedures, and make complex decisions in
a changing environment. However, current DM treatment
and surveillance do not include routine assessment of
cognitive function and the cognitive function of the indi-
vidual is not taken into consideration when devising a
treatment plan. This is especially important when treating
older people with DM, since DM and aging are both
independent risk factors for cognitive dysfunction. In the
face of increasing numbers of older people with DM the
fact that cognitive impairment is another complication of
DM has two important implications. One is that it is pivotal
that the effect of currently used glucose lowering agents on
this complication be understood. Second, cognitive
assessment, i.e., screening and surveillance should be part
of the routine care of the older person with DM.
Cognitive dysfunction can potentially present new bar-
riers to self-care and to achieving glycemic control. Indeed,
population studies have shown that among people with DM
lower cognitive function was associated with worse effi-
cacy of treatment indices such as glucose control
(Cukierman-Yaffe et al. 2009) and a greater risk for inci-
dent hypoglycemia (Punthakee et al. 2012). Reciprocal
associations are assumed between DM self-care, glycemic
control, micro and macro vascular outcomes, and cognitive
impairment. Indeed, in a sample of 1398 older community-
dwelling adults with DM, as cognitive impairment wors-
ened, so did participants’ adherence to each diabetes self-
care task with incremental increases in DM comorbidity
(Esmaeili et al. 2016). In a population-based study,
amongst *3000 middle-aged individuals with diabetes,
those with lower cognitive scores had a higher risk for
hypoglycemia events that required the help of another (a
possible sequel of poor self-care management skills as it
requires the patient to be self-alert and active in the man-
agement of the disease) (Punthakee et al. 2012). Another
study reported that providing memory strategies improved
adherence to medication amongst elderly DM patients
(Vedhara et al. 2010). Finally, a recent study reported that
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in individuals with DM, lower executive function was
associated with higher need of outpatient care.
Current guidelines for treating older people with DM rec-
ommend routine screening for cognitive dysfunction (Kirk-
man et al. 2012; Sinclair et al. 2015). However, cognitive
dysfunction is only the tip of the iceberg of a continuum of
cognitive decline which is accelerated in people with DM.
Thus, it is also important to characterize the cognitive profile
of the intact individual with DM enabling care takers to adapt
the treatment plan according to the individual’s cognitive
capacities. Indeed, in the past 3 years at the Center for Suc-
cessful aging with Diabetes at the Sheba Medical Center,
Israel, we have been conducting multi-disciplinary evaluation
that include extensive neuropsychological testing and evalu-
ation of the medical, functional, and physical status of the
older person with DM, followed by cognitively adapted tailor-
made recommendations (including the use of cognitive
rehabilitation strategies) and a follow-up plan that takes into
consideration the cognitive profile of the individual. Partici-
pants have reported a significant improvement in quality of
life. We hypothesize that this type of approach which includes
cognitive screening, surveillance, and rehabilitation will
improve the self-care capacity of the older individual with
DM, thus improving glucose control and reducing the risk for
DM complications and possibly reducing the accelerated rate
of cognitive decline this population experiences.
When deciding which drug to add to the regimen of an
older individual with DM, the potential risk for hypo-
glycemia with this agent should be evaluated. Hypo-
glycemia unawareness is very common in elderly DM
patients. A study involving T2DM patients over 65 years
of age and using continuous glucose monitoring revealed
hypoglycemic episodes in as many as 80% of patients,
including 56% with severe hypoglycemic episodes
(\40 mg/dl), and none of these episodes were actually
‘‘felt’’ by a patient (Kagansky et al. 2003; Zoungas et al.
2010; Whitmer et al. 2009; Sinclair et al. 2011; Kasiukie-
wicz et al. 2015; Tseng et al. 2014). Thus, the type of
glucose lowering agent chosen should take into consider-
ation hypoglycemia unawareness as well as the cognitive
profile of the older person with diabetes choosing therapy
that is safer in this respect such as metformin, alpha-glu-
cosidase inhibitors, thiazolidinediones, GLP-1 receptor
agonists, DPP-4 inhibitors, SGLT-2 as opposed to insulin,
sulfonylureas, or glinides (Chamberlain et al. 2016).
Differences between treated and not treated DM2
patients
T2DM patients may be treated with oral antidiabetic agents
[such as sulfonylurea, metformin and dipeptidyl peptidase
4 inhibitor (DPP-4I)], insulin, or by diet control only.
Although all treatments may reduce glucose level, which
type of treatment is helpful in reducing the cognitive
impairment, is not clear.
Early studies suggest that cognitive decline may be
slower, if T2DM patients are treated with insulin instead
than oral antidiabetic agents. Therapy with insulin may
lower neuritic plaque density in hippocampus and other
brain areas (Beeri et al. 2008). In addition, Plastino et al.
demonstrated slower cognitive decline in T2DM patients
with AD treated with insulin in comparison to patients
treated with oral antidiabetic agents (Plastino et al. 2010).
However, this relationship may not be straight forward. In
a recent study, Herath et al. followed T2DM patients for
4 years and found no significant differences between
patients from diet only, oral antidiabetic agents, and insulin
groups (Herath et al. 2016).
New research shows that treatment with DPP-4 inhibi-
tors (DPP4I) is helpful. Rizzo et al. demonstrated in a
prospective 2-year study that patients treated with DPP4I
and metformin had better cognitive functioning in com-
parison to patients treated only with sulphonyl urea and
metformin (Rizzo et al. 2014). Similar results were found
in a shorter study, where they followed patients for
6 months (Isik et al. 2017). T2DM patients with AD and
without AD treated with DPP-4I performed better on
MMSE 6 months after they started with the treatment than
patients taking metformin (Isik et al. 2017). In addition,
patients treated with insulin or DPP-4I also had better
glucose control and lower HbA1c at the end visit.
Future strategies
Increasing evidence suggests that the production of new
neurons in the adult hippocampus (adult neurogenesis; AN)
plays an important role in different subtypes of learning
processes and memory formations (Deng et al. 2009a, b)
and seems also to contribute to cognitive flexibility (Bur-
ghardt et al. 2012). Indeed, hippocampal AN was demon-
strated to be diminished in these icv STZ rats after
3 months (Sun et al. 2015).
Therefore, it has been suggested that altered AN in the
hippocampus plays a role in the etiopathology of neu-
rodegenerative disorders such as AD (for review, see
Winner and Winkler 2015) and vascular dementia (Eko-
nomou et al. 2011). Cerebrovascular functions and AN
both decline during aging (Kalaria 2009; Kempermann
2015) which stands to reason as AN occurs within an
angiogenic niche (Palmer et al. 2000). Improved energy
supply in experimental AN studies show improved AN
when using DM related therapeutic strategies (Luitse et al.
2012; Biessels 2013; Sonnen et al. 2009; Jia et al. 2004;
Tohgi et al. 1996; Chen et al. 2013; Lee et al. 2014; Niwa
P. Riederer et al.
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et al. 2002), indicating an important role of glucose/energy
supply for the proper integrity of AN physiology.
Conclusion
In many individuals, AD and VaD show an underlying
pathology of glucose utilization based on a disturbance of
insulin-related pathology, leading to a brain insulin resis-
tance state. However, the risk factors rather induce a
mechanisms independent from pathological mechanisms
underlying AD and VaD. In fact, these probably have
different causality, which is reflected in the prevalence/
incidence of AD (about 60%) and VaD (about 20%) of all
dementia disorders. Considering the brain insulin resis-
tance as a shared pathological feature of T2DM and
dementia which, most probably are a consequence of
environmental factors and epigenetic mechanisms operat-
ing during pregnancy and postnatally may be manifested as
one or the other disorder, T2DM contributes to disease
onset and progression of both AD and VaD. Therefore,
therapeutic strategies focusing on DM should be consid-
ered already in early stages of AD and VaD. Future
strategies including AN may enlarge the therapeutic
armamentarium. More focus should be put on delaying
dementia onset in people with diabetes and on the chal-
lenges cognitive impairment imposes on the self-care
capacity of this population.
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